- Published on
Amping up T cells to target cancer
- Authors
- Name
- DeepHorus
Researchers from MIT, Harvard, and the University of Houston have developed a novel approach to supercharge the immune system's T cells to better fight cancer and infectious diseases. The team, led by MIT chemical engineer Daniel Anderson, created a new type of vaccine adjuvant using mRNA molecules that can 'remodel' immune cells into a more active state. This advance aims to solve a key limitation of current mRNA cancer vaccines, which often fail to stimulate a sufficient immune response in many patients.
The new adjuvant consists of lipid nanoparticles containing mRNA that encodes two genes. These genes activate specific signaling pathways, effectively reprogramming immune cells. Unlike traditional methods that use cytokine moleculesâwhich can cause severe side effectsâthis mRNA-based adjuvant offers a potentially safer way to significantly boost the T-cell response to a vaccine.
In preclinical studies with mice, the results were dramatic. When the adjuvant was administered alongside cancer vaccines, it generated a T-cell response 10 to 15 times stronger than usual. This powerful enhancement allowed the immune system to slow tumor growth or eradicate cancers entirely in models of bladder, colon, melanoma, and metastatic lung cancer.
Crucially, the adjuvant also proved effective even without a specific cancer antigen vaccine, suggesting a broader remodeling of the immune environment. It further enhanced the efficacy of checkpoint blockade inhibitors, which are a class of FDA-approved immunotherapy drugs. Researchers noted it creates a 'T-cell-permissive environment' within the hostile microenvironment of solid tumors.
The technology shows equal promise for infectious diseases. When tested alongside COVID-19 or flu vaccines in mice, the adjuvant similarly amplified the T-cell response by 10 to 15 fold. This could lead to far more effective vaccines for a range of viral threats.
The research team plans further testing in additional animal models. The ultimate goal is to develop this approach for clinical use in both oncology and infectious disease prevention. The work represents a significant step toward next-generation immunotherapies that are both more powerful and potentially safer.
This development from Anderson's group is part of a broader wave of adjuvant innovation at MIT. For instance, another team led by Ana Jaklenec is using an adjuvant to help an injectable polio vaccine induce strong mucosal immunity, a key objective in global eradication efforts. These parallel advances highlight the growing role of advanced adjuvant technology in modern medicine.
